Galderma marks the 10th anniversary of its premium medical skincare brand Alastin with the launch of four core products in China, each formulated to support the skin’s natural regenerative abilities to help with skin recovery before and after aesthetic procedures1,2
This is the first launch to feature Alastin’s new packaging and builds on its strong growth in key markets including the United States, Canada, and the United Kingdom
As the demand for perioperative skincare accelerates, this expansion shows Galderma’s commitment to delivering science-backed products that drive superior outcomes for even more patients3-6

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand’s debut in one of the world’s fastest growing aesthetic skincare markets.6-8 This is the first launch to feature Alastin by Galderma’s new re-energized, premium look and feel, a bold evolution that reflects its leadership in perioperative skincare.

Alastin offers full-spectrum care for patients undergoing aesthetic procedures, from pre-treatment preparation to post-treatment recovery and at-home maintenance, supporting the skin’s natural regenerative abilities to improve overall skincare results.1,2,9-13 With over 50 global dermatological publications and 22 patents, Alastin is strongly backed by science and is the number one peri-procedural skincare brand in the United States.14-16 This launch follows the strong growth of Alastin in other key markets and demonstrates Galderma’s commitment to addressing the needs of patients with science-backed solutions.

Comprehensive perioperative solutions addressing growing needs

Four core Alastin products that cover all stages of the aesthetic treatment process will now be available in China, creating an integrated in-clinic and at-home skincare program:

• Regenerating Skin Nectar to optimize visible treatment results9
• HA (Hyaluronic Acid) IMMERSE Serum™ to hydrate and support skin barrier repair10
• INhance Serum helps to enable quicker recovery after treatment with injectables, improving the appearance of the skin post-injection11
• Restorative Skin Complex to support aesthetic treatment results by helping to reduce the visible signs of aging12

This comprehensive perioperative series of regenerative skincare products advances aesthetic treatments from isolated procedures to full-spectrum management.1,2,9-12 It reflects Galderma’s holistic approach to aesthetic care – working across its Dermatological Skincare and Injectable Aesthetics portfolios to ensure that products complement each other, delivering seamless, science-backed solutions that elevate patient outcomes.1,2,9-13 Select products are powered by proprietary TriHex Technology® to further enhance skin regeneration and recovery.1,2,13

China’s medical aesthetics market is experiencing remarkable growth, and is projected to increase by up to 15% in the next decade.17 As aesthetic treatments become increasingly mainstream there is rising demand for perioperative skincare, with consumers willing to invest in advanced technologies and premium products to achieve optimal aesthetic outcomes.3-6,17 With its proven efficacy and full-spectrum approach to pre- and post-procedure care, as well as at-home maintenance, Alastin by Galderma is uniquely positioned to address this need.1,2,6-9

This launch marks ten years of pioneering innovation with Alastin, demonstrating Galderma’s commitment to purposeful growth with the brand’s refreshed premium look and feel, and entry into one of the fastest growing aesthetic skincare markets. Following strong growth in North America, Latin America, Australia, and the U.K. & Ireland, Alastin is now undergoing rapid international expansion, offering its premium products to even more patients. By identifying emerging patient needs and delivering science-backed solutions, Galderma continues to shape the future of dermatology and elevate outcomes across the aesthetic journey.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Contacts

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43